Pulmonary arterial hypertension (PAH) is the increase in mean pulmonary arterial pressure (> 25 mmHg). The development of the non-reversible plexiform lesions on the arterial walls of the pulmonary arteries has evolved as the reason to increase the pressure. The current treatments are directed towards the vasodilation of the pulmonary arteries via the endothelin, prostacyclin, and NO pathways which provides symptomatic relief. Deeper understanding of the disease leads to the various pathophysiological targets that play an important role in the development of PAH. Out of these, the angiogenetic mechanism of the pulmonary arterial smooth muscle cells has been proved to play an important role in PAH. Targeted therapies by anti-proliferative drugs may lead to the efficient treatment strategies to the root cause of PAH. Erlotinib, a receptor tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor (EGFR), has shown promising results in clinical trials of PAH. The objective of the work has been the development of liposomal formulation of anti-proliferative drug, erlotinib HCl, via Quality by Design (QbD) approach. The liposomal formulation was developed using thin-film hydration technique and characterised for various physicochemical parameters, like particle size, % entrapment efficiency, DSC, FTIR, pXRD, and TEM. In the drug release study, the formulation showed sustained release of erlotinib over 24 h in simulated lung fluid pH 7.4. This developed formulation was evaluated in zebrafish tail fin regeneration assay for its anti-angiogenetic activity. The liposomal formulation inhibited the tail fin regeneration for 14 days indicating anti-angiogenetic activity.
Pulmonary arterial hypertension Angiogenesis Quality by Design Liposomes Zebrafish
This is a preview of subscription content, log in to check access.
Ethical approval and animal care and use
All institutional and national guidelines for care and use of laboratory animals were followed.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Smythe W, Mcilleron H, Merle C, Horton J, Smith P, Simonsson, USH. A semi-mechanistic pharmacokinetic auto-induction model for the characterisation of rifampicin pharmacokinetics in African pulmonary tuberculosis infected adults. Poster Abstracts page 2010, 39.Google Scholar
Frumkin LR. The pharmacological treatment of pulmonary arterial hypertension. Pharmacol Rev. 2012;64(3):583–620.CrossRefPubMedGoogle Scholar
Vaidya B, Gupta V. Novel therapeutic approaches for pulmonary arterial hypertension: unique molecular targets to site-specific drug delivery. J Control Release. 2015;211:118–33.CrossRefPubMedGoogle Scholar
Galie N, Ghofrani A-H. New horizons in pulmonary arterial hypertension therapies. Eur Respir Rev. 2013;22(130):503–14.CrossRefPubMedGoogle Scholar
Chakraborty C, Hsu CH, Wen ZH, Lin CS, Agoramoorthy G. Zebrafish: a complete animal model for in vivo drug discovery and development. Curr Drug Metab. 2009;10(2):116–24.CrossRefPubMedGoogle Scholar
Rubinstein AL. Zebrafish: from disease modeling to drug discovery. Curr Opin Drug Di De. 2003;6:218–23.Google Scholar
Chávez MN, Aedo G, Fierro FA, Allende ML, Egaña JT. Zebrafish as an emerging model organism to study angiogenesis in development and regeneration. Front Physiol. 2016;7(MAR):1–15.Google Scholar
Xu H, He C, Liu Y, Jiang J, Ma T. Novel therapeutic modalities and drug delivery—erlotinib liposomes modified with galactosylated lipid: in vitro and in vivo investigations. Artif Cell Nanomed B. 2018;46(8):1902–7.Google Scholar
Nimmano N, Somavarapu S, Taylor KM. Aerosol characterisation of nebulised liposomes co-loaded with erlotinib and genistein using an abbreviated cascade impactor method. Int J Pharm. 2018;542(1–2):8–17.CrossRefPubMedGoogle Scholar
Pitsiou G, Zarogoulidis P, Petridis D, Kioumis I, Lampaki S, Organtzis J, et al. Inhaled tyrosine kinase inhibitors for pulmonary hypertension: a possible future treatment. Drug Des Dev Ther. 2014;8:1753–63.Google Scholar
Xu X, Khan MA, Burgess DJ. A quality by design (QbD) case study on liposomes containing hydrophilic API: II. Screening of critical variables, and establishment of design space at laboratory scale. Int J Pharm. 2012;423(2):543–53.CrossRefPubMedGoogle Scholar
Sylvester B, Porfire A, Muntean DM, Vlase L, Lupuţ L, Licarete E, et al. Optimization of prednisolone-loaded long-circulating liposomes via application of quality by design (QbD) approach. J Lipos Res. 2018;28(1):49–61.CrossRefGoogle Scholar
ICH. Pharmaceutical development Q8. ICH Harmon Tripart Guidel. 2009;8(August):1–28.Google Scholar
Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003;56(6):588–99.CrossRefPubMedPubMedCentralGoogle Scholar
ICH Expert Working Group. Quality risk management Q9. ICH Harmon Tripart Guidel. 2005;(November):1–23.Google Scholar
Roy B, Guha P, Bhattarai R, Nahak P, Karmakar G, Chettri P, et al. Influence of lipid composition, pH, and temperature on physicochemical properties of liposomes with curcumin as model drug. J Oleo Sci. 2016;65(5):399–411.CrossRefPubMedGoogle Scholar
Mahmoud M, Labiba N, Khalil EK, Khalafallah N. Effect of various formulation variables on the encapsulation and stability of dibucaine base in multilamellar vesicles. Acta Pol Pharm Drug Res. 2005;62(5):369–79.Google Scholar
Kulkarni SB, Betageri GV, Singh M. Factors affecting microencapsulation of drugs in liposomes. J Microencapsul. 1995;12(3):229–46.CrossRefPubMedGoogle Scholar
Makrilia N, Lappa T, Xyla V, Nikolaidis I, Syrigos K. The role of angiogenesis in solid tumours: an overview. Eur J Intern Med. 2009;20(7):663–71.CrossRefPubMedGoogle Scholar
Poss KD, Keating MT, Nechiporuk A. Tales of regeneration in zebrafish. Dev Dynam. 2003;226(2):202–10.CrossRefGoogle Scholar
Eyries M, Siegfried G, Ciumas M, Montagne K, Agrapart M, Lebrin F, et al. Hypoxia-induced apelin expression regulates endothelial cell proliferation and regenerative angiogenesis. Circ Res. 2008;103(4):432–40.CrossRefPubMedGoogle Scholar
Rathinasamy VS, Paneerselvan N, Jagadeeshan S, Malathi R. Hypoxia induced angiogenesis and upregulation of VEGF: an in vivo study using zebrafish model. Int J Sci Eng Res. 2015;6(6):831–9.Google Scholar